Ivonescimab 依沃西单抗(AK112)是一种 PD-1/VEGF 双特异性抗体。Ivonescimab 可用于癌症研究。 Ivonescimab 可与 PD-1 和 VEGFA 结合，EC50 分别为 0.06 和 0.036 nM。 Ivonescimab 可与 VEGF 形成可溶性复合物 (通过 SEC-HPLC 检测)。 Ivonescimab is a pioneering humanized tetravalent bispecific antibody that targets PD-1 and VEGF-A, exhibiting immune checkpoint inhibition, anti-angiogenic, and anti-tumor activities. This innovative therapy is currently under development for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast cancer, liver cancer, and gastric cancer. The molecular weight of Ivonescimab is 201.12 kDa.

参考文献

[1]. Coward J, et al. Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. Journal for Immuno Therapy of Cancer 2021;9:

[2]. Zhong T, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. Journal for Immuno Therapy of Cancer. 2022;10:

[3]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Journal for Immuno Therapy of Cancer. 2022;10:e005517.